Compare Campbell Soup Co. (CPB) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs BIO-TECHNE Corp — how do they compare? Campbell Soup Co. trades at $19.38 (market cap $5.78B), while BIO-TECHNE Corp trades at $72.5 (market cap $11.36B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Campbell Soup Co. pays the higher dividend (5.16%). Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and BIO-TECHNE Corp for 64 Days on average.
| CPB | TECH | |
|---|---|---|
Market Cap | $5.78B | $11.36B |
Volume | 11,705,427 | 5,390,331 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $72.61 |
52-Week Low | $18.90 | $43.31 |
Typical Hold Time | 98 Days | 64 Days |
Enterprise Value | $12.83B | $11.39B |
Dividend Yield | 5.16% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $19.12, up 1.16% on the day, with a bearish technical outlook and mixed analyst sentiment. The company reported a Q4 2026 earnings miss but beat expectations in Q1 and Q2 2026. Recent developments include a 36% dividend cut, a $500 million cost savings program, and workforce reductions. Valuation metrics show a P/E of 14.79 and P/S of 0.6, suggesting potential undervaluation amid operational challenges.
The outlook remains cautious due to margin pressure and declining sales, though cost-cutting initiatives and brand strength in segments like Rao's offer long-term potential. Key risks include execution of turnaround plans and competitive pressures. The consensus price target is $19.73, with most analysts rating Hold.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
